Pfizer Inc. (NYSE:PFE) Shares Sold by Scotia Capital Inc.

Scotia Capital Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 29.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 794,246 shares of the biopharmaceutical company’s stock after selling 328,203 shares during the quarter. Scotia Capital Inc.’s holdings in Pfizer were worth $21,073,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer during the 4th quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 3.0 %

Pfizer stock opened at $22.50 on Thursday. The company’s fifty day simple moving average is $25.42 and its 200-day simple moving average is $26.51. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market cap of $127.61 billion, a P/E ratio of 15.96, a P/E/G ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group reduced their target price on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $31.07.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.